Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
0.3759
Dollar change
-0.0116
Percentage change
-2.99
%
Index- P/E- EPS (ttm)-1.31 Insider Own70.78% Shs Outstand29.65M Perf Week-14.35%
Market Cap11.27M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float8.76M Perf Month-50.99%
Income-38.89M PEG- EPS next Q-0.27 Inst Own6.99% Short Float / Ratio3.37% / 1.28 Perf Quarter-69.93%
Sales30.00M P/S0.38 EPS this Y22.42% Inst Trans-12.47% Short Interest0.29M Perf Half Y-74.94%
Book/sh0.59 P/B0.63 EPS next Y12.50% ROA-39.52% Target Price4.00 Perf Year-66.73%
Cash/sh1.39 P/C0.27 EPS next 5Y- ROE-76.49% 52W Range0.30 - 3.32 Perf YTD-68.68%
Dividend- P/FCF- EPS past 5Y- ROI-48.95% 52W High-88.68% Beta1.64
Dividend %- Quick Ratio1.91 Sales past 5Y84.41% Gross Margin53.87% 52W Low25.30% ATR0.07
Employees243 Current Ratio2.07 Sales Q/Q-16.64% Oper. Margin-123.14% RSI (14)34.20 Volatility10.86% 21.97%
OptionableYes Debt/Eq1.07 EPS Q/Q10.35% Profit Margin-129.63% Rel Volume0.19 Prev Close0.39
ShortableYes LT Debt/Eq0.71 EarningsNov 13 AMC Payout- Avg Volume230.26K Price0.38
Recom1.67 SMA20-11.81% SMA50-46.60% SMA200-76.08% Volume42,736 Change-2.99%
Nov-13-23 05:32PM
04:22PM
Nov-07-23 09:00AM
Nov-03-23 12:00PM
Sep-28-23 03:48PM
04:05PM Loading…
Aug-29-23 04:05PM
Aug-10-23 04:51PM
04:05PM
Aug-03-23 05:00PM
Jun-08-23 09:05AM
Jun-06-23 03:00AM
Jun-05-23 05:30PM
May-31-23 05:29PM
May-23-23 09:00AM
May-22-23 12:00PM
10:00AM Loading…
May-18-23 10:00AM
May-15-23 09:00AM
May-13-23 08:05AM
May-12-23 04:17PM
May-11-23 05:25PM
04:22PM
04:05PM
Apr-27-23 04:05PM
Apr-17-23 07:50AM
06:47AM
Mar-31-23 09:00AM
Mar-28-23 04:59AM
Mar-25-23 08:21AM
Mar-21-23 05:25PM
04:05PM
06:00AM Loading…
Mar-16-23 06:00AM
Mar-14-23 06:00AM
Mar-09-23 04:30PM
Feb-27-23 09:00AM
Feb-16-23 09:00AM
Jan-09-23 09:00AM
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nelson Todd RobertPresident & CEOMay 04Sale2.832,5757,277136,072May 08 08:11 PM
Gibson Daniel GlennChief Technology OfficerMay 04Sale2.831,1903,363102,083May 08 08:09 PM
Cutler RobChief Legal OfficerMay 04Sale2.831,1743,31825,468May 08 08:06 PM